Tag Archives: trials

Protect readers’ time and bandwidth from unpublished trials

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Photo: Thomas Leuthard via Flickr

Every week for years, I’ve received press releases about studies starting up. This one looking at heart disease, that one about a common cancer, and still another on a rare childhood disease. I’ve written about precisely zero of them. When the public relations person follows up, I’ll explain: “I write primarily about peer-reviewed research. Let me know when it’s published.”

If you write for business, pharma or medical trade publications, there may be times when you write about the initiation of a study. Even then, it’s typically more important to wait until the study is actually underway and there’s something to say about it. And for consumer publications, I can’t think of any reason to talk about an upcoming individual study that hasn’t begun. Continue reading

Fauci’s announcement of remdesivir trial findings leaves out crucial detail

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Most of the time, the most important aspect of reporting on medical research is ensuring that the coverage is accurate, precise, clear and understandable to the average reader, and includes adequate context, including cost, side effects, alternative treatments and previous data. Other times, the medium, or, rather, the literal physical setting and the framing surrounding the message, matter as much or more, as some have argued regarding Anthony Fauci’s recent announcement about the NIH trial findings on remdesivir from the Oval Office couch.

But, as Gary Schwitzer points out in his most recent blog post at HealthNewsReview.com, other details can be utterly crucial to the public’s understanding about potentially important findings about a drug, particularly during a pandemic: What a particular study was intended to do in the first place. Continue reading

Caveats about causality in medical studies linked to more accurate news coverage

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Photo: Jacob via Flickr

It’s a well-worn mantra: Correlation does not equal causation. But even if we know this, is it always accurately and responsibly reflected in our stories and headlines?

It can be simpler and more elegant to say “Vodka causes sexually transmitted infections” in a headline than “Vodka consumption associated with increased risk of sexually transmitted infections.” (Note: This is not a real headline or based on a real study.) But in this made-up example, it’s laughably obvious that vodka itself does not cause STDs. Continue reading

New tip sheet details cancer diagnosis and treatment in older adults

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Kim Brookes via Flickr

Cancer diagnosis and care are complex. When comorbid conditions, multiple medications, changing physiology and decreasing resilience are involved, they present further challenges for many patients and their cancer specialists. How can they treat a serious disease while minimizing the risk of mortality, side effects, and diminished quality of life?

The good news is that people generally are living longer. The downside is that with increased longevity comes increased odds of developing various forms of cancer. Continue reading

Do you have all the evidence on a drug that you’re reporting about?

Tara Haelle

About Tara Haelle

Tara Haelle (@TaraHaelle) is AHCJ's medical studies core topic leader, guiding journalists through the jargon-filled shorthand of science and research and enabling them to translate the evidence into accurate information.

Photo: Esther Dyson via Flickr

The registration and reporting requirements of Clinicaltrials.gov are vital to informing the evidence base – but only if study sponsors actually use it and keep entries updated. A recent research letter in JAMA Internal Medicine suggests this is not happening often enough. That’s helpful for journalists to know if they are attempting to find all the recent evidence on a particular drug or intervention.

“Missing or incomplete reporting of clinical trial results and its scientific and ethical consequences are well documented,” wrote Kevin M. Fain, J.D., M.P.H., Dr.PH, and his team at the National Institutes of Health.

Continue reading

New approach treats Alzheimer’s one person at a time

Liz Seegert

About Liz Seegert

Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.

Photo: Iriss via Flickr

Can a precision medicine approach to Alzheimer’s disease (AD) and other dementias improve outcomes?

That is the theory behind the Dementia Prevention Initiative (DPI). The Florida Atlantic University (FAU) program twists the usual methods used to research and treat AD by employing an “n-of-1” design individualize medicine down to a single patient. Instead of conducting a conventional trial of 100 people who get the same treatment, the program conducts 100 single trials personalized to the individual. The youngest DPI patient is currently 61, and the oldest is 86. Continue reading